Results
1 -
10 of
50Overview of PARP Inhibitor Design and Optimization, PARP Inhibitors for Cancer Therapy PARP, Cancer Therapeutic Targets Clinical Trials of PARP Inhibitors with Chemotherapy, PARP Inhibitors for Cancer Therapy Preclinical Chemosensitization by PARP Inhibitors, PARP Inhibitors for Cancer Therapy Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents, PARP Inhibitors for Cancer Therapy Introduction to PARPi Clinical Trials and Future Directions, PARP Inhibitors for Cancer Therapy A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation, Cancer Chemotherapy and Pharmacology Clinical Anticancer Drugs for Cancer Treatment, Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy Advances in Ovarian Cancer and Ongoing Clinical Trials, Gynecological Cancers Clinical Trials Investigating PARP Inhibitors as Single Agents, PARP Inhibitors for Cancer Therapy